Immunogenicity of partial doses of live oral cholera vaccine CVD 103-HgR in children in the United States.
Vaccine
; 41(17): 2739-2742, 2023 04 24.
Article
en En
| MEDLINE
| ID: mdl-36959054
ABSTRACT
In a phase 4, placebo-controlled, double-blind, multi-center study performed to assess the immunogenicity of a single oral dose of live, attenuated cholera vaccine, volunteers aged 2-17 years were randomized 61 to receive 1 × 109 colony forming units of PXVX0200 or placebo. In the subset of subjects who consumed < 80 % of the vaccine dose, seroconversion rates were calculated and stratified by amount consumed. Of 468 subjects dosed, a subset of 33 (7 %) received < 80 % of the vaccine dose. SVA seroconversion occurred in 75.8 % of these subjects, including 100 % (7/7) of those who took 50-80 % and 69.2 % (18/26) of those who took < 50 %, versus 98.5 % of those who consumed 80 % or more. Vaccination with PXVX0200 produced an immune response in most children who received partial dosing. Since SVA seroconversion is a strong correlate of protection, PXVX0200 may protect against cholera infection in children who ingest only part of the vaccine dose.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
1_ASSA2030
/
2_ODS3
/
3_ND
Problema de salud:
1_doencas_transmissiveis
/
2_enfermedades_transmissibles
/
3_cholera
/
3_neglected_diseases
Asunto principal:
Vacunas contra el Cólera
/
Cólera
Tipo de estudio:
Clinical_trials
Límite:
Child
/
Humans
País/Región como asunto:
America do norte
Idioma:
En
Revista:
Vaccine
Año:
2023
Tipo del documento:
Article